

# Serum selenium and glutathione peroxidase concentrations in healthy Iranian subjects

Mohammad Safarian<sup>a,1</sup>, Homa Hosseinpoor<sup>b,1</sup>, Mohammad Reza Parizadeh<sup>a</sup>, Mohsen Mazidi<sup>a</sup>, Samaneh Tabae<sup>c</sup>, Shima Tavallaie<sup>d</sup>, Majid Ghayour-Mobarhan<sup>a,\*</sup>, Habibollah Esmaily<sup>c</sup> and Gordon A.A. Ferns<sup>f</sup>

<sup>a</sup>*Biochemistry of Nutrition Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran*

<sup>b</sup>*Department of Biochemistry and Nutrition, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran*

<sup>c</sup>*Cardiovascular Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran*

<sup>d</sup>*Department of Biochemistry and Nutrition, Biochemistry of Nutrition Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran*

<sup>e</sup>*Centers for Health Sciences Research, School of Health, Mashhad University of Medical Sciences, Mashhad, Iran*

<sup>f</sup>*Division of Medical Education, Brighton & Sussex Medical School, Mayfield House, University of Brighton, United Kingdom*

## Abstract.

**BACKGROUND AND AIM:** We have investigated the association between serum selenium and GPx concentrations, demographic characteristics, anthropometric features, fasting lipid profile and blood glucose levels, in healthy subjects.

**METHODS:** Serum selenium was measured by atomic absorption spectrometry in 197 healthy subjects. Serum glutathione peroxidase, fasting lipid profile, and blood glucose levels were also determined for each subject. Anthropometric features including blood pressure and body mass index were determined using standard procedures.

**RESULTS:** The mean serum selenium in the whole subjects group was  $116 \pm 27.73 \mu\text{g/l}$  (range 44–209  $\mu\text{g/l}$ ). Serum Selenium and GPX concentration did not vary significantly with gender and smoking habit. Significant differences were observed in serum selenium and GPx concentration with age ( $P < 0.05$  and  $P < 0.02$  respectively). Obese subjects had significantly lower serum concentrations of GPx ( $r = 0.281$ ,  $P = 0.01$ ). Serum GPx concentrations were inversely related to weight ( $P = 0.01$ ), systolic blood pressure ( $P < 0.01$ ), fasting blood sugar ( $P < 0.01$ ), serum low-density lipoprotein-cholesterol (LDL-C) ( $P = 0.01$ ), serum triglycerides ( $P < 0.01$ ), and positively associated with fasting total cholesterol levels. The corresponding predictors for serum selenium level were diastolic blood pressure ( $P < 0.05$ ) and serum triglycerides level ( $P = 0.05$ ), which were inversely related.

**CONCLUSION:** Serum concentration of selenium in an Iranian healthy population is higher than most countries however, similar to the US and UK. Moreover, serum selenium and GPx concentrations appear to be influenced by physiological factors including age. Their serum concentrations were also associated with coronary risk factors, including serum total cholesterol and serum triglycerides levels.

Keywords: Selenium, GPx, healthy adults

## 1. Introduction

Selenium is an important trace element; selenium is part of the active site of the enzyme glutathione peroxidase antioxidant (GSH-Px). Selenium is a modulator of the response to oxidative stress and selenium supplements have been reported to result in a faster restoration of the endogenous antioxidative defense system against the production of

<sup>1</sup>Two authors regard as same contribution.

\*Corresponding author: Majid Ghayour-Mobarhan, Cardiovascular Research Center, School of Medicine, Mashhad University of Medical Science, Mashhad, Iran. Post code: 9138813944, Mashhad, Iran. Tel.: +98 9155171478; Fax: +98 511 7112596; E-mail: ghayourm@mums.ac.ir.

reactive oxygen species [1]. Free radicals are thought to play an important role in the pathogenesis of coronary heart disease (CHD) and carcinogenesis [2, 3]. Epidemiological studies show an inverse relationship between selenium intake and cancer incidence, and mortality [4]. Furthermore, selenium has a narrow therapeutic range [5] and high selenium concentrations have been associated with increased lipid levels [6] and higher prevalence of hypertension [7] and diabetes [8, 9]. However, the interpretation of these studies may be confounded by variables that contribute to disease risk, that also affect trace element status [10]. Therefore, determining the relationship between a number of factors that have been reported or may be expected to affect trace element status and serum selenium concentration may contribute to better assessing the health and nutritional status of certain population. In the present study, we aimed to evaluate the influence of demographic characteristics and lifestyle factors on plasma levels of selenium in the adult population in Iran.

## 2. Material and methods

### 2.1. Subjects

Approximately 197 healthy subjects (80 men, 117 women; mean 38.5 age: years, range: 18–80 years) were enrolled in our study. The socio-economic status of all subjects corresponded to the middle-class Iranian population. They had comparable level of activity. Subjects who were on vitamin supplements, lipid-lowering medications, oral contraceptives, or hormone replacement therapy were excluded from the study. Pregnant women were also excluded. All subjects gave informed written consent to participate in the study, which was approved by Mashhad University of Medical Science Ethics Committee. In addition, a standardized questionnaire was also filled-out by individuals to provide information on age, gender, socioeconomic status and smoking habits, etc.

### 2.2. Anthropometric measurement

For anthropometric measurements including weight and height standard protocol were used. The subjects were shoeless and dressed in very light clothing after overnight fast. Body weight was measured with a portable digital standard scale to accuracy of  $\pm 0.1$  Kg, and height was measured with a portable stadiometer to an accuracy of  $\pm 0.1$  cm. Body mass index (BMI) was calculated as weight divided by height square<sup>2</sup> (m).

### 2.3. Blood collection

Blood samples were collected in the morning from each subject after overnight fast by venepuncture of the ante-cubital vein. After being allowed to clot, it was centrifuged at 2500 rpm for 15 min at room temperature to obtain serum, taking care to avoid possible sources of trace element contamination. Serum was stored at  $-20^{\circ}\text{C}$  before analysis.

A full-fast lipid profile was determined for each subject. LDL cholesterol was calculated using the Friedewald equation, except for subjects with triglyceride concentrations of  $>4.0$  mmol/L. Serum lipid and fasting blood sugar concentrations were measured by enzymatic methods.

Selenium was determined by electro-thermal atomic absorption spectrometry with Zeeman background correction using a palladium chloride chemical modifier [11].

### 2.4. GPx assay

Serum GPx was measured using a modification of the method of Paglia and Valentine [12]. Briefly, 10 mL of serum, standard (0.1–0.3 U/mL purified GPx) or water (blank) was added in quadruplicate to a 96-well plate. In all, 290  $\mu\text{L}$  of 0.1 mol/L phosphate buffer (containing 5 mmol/L EDTA, 200  $\mu\text{mol/L}$  sodiumazide, 1 U/mL glutathione reductase, 0.86 mmol/L NADPH, 2 mmol/L reduced glutathione and 7.8 mmol/L t-butyl hydroperoxide) was added

to each well. The reagents were mixed and the absorbance at 340 nm measured continuously for 5 min in an iEMS MF plate reader. The between assay CV was typically 5.5%.

### 2.5. Statistical analysis

The data were subjected to statistical evaluation using MiniTab (release 13, Minitab Inc, 2000, USA), with descriptive statistics (mean, medium, standard deviation [SD], and interquartile range) being determined for all variables. The Kolmogorov-Smirnov's test was carried out to examine if the variables had a normal distribution ( $P < 0.05$ ). The mean values of different groups were compared by one-way ANOVA and Student's *t*-test. Categorical data were compared using Fisher's exact or  $\chi^2$  tests. Stepwise multiple regression analysis was used to predict whether serum trace element was related to factors such as age, gender, smoking, BMI, fasting blood glucose, lipid profile, and systolic and diastolic blood pressure. *P* value  $< 0.05$  was considered significant.

## 3. Results

A total of 197 healthy persons were enrolled in our study, of this group, 80 (40.6%) were men and 117 (59.4%) were women. The mean age of subjects was  $38.5 \pm 16.5$  years (Table 1). The mean serum selenium and GPx concentrations in the whole subjects group was  $116 \pm 27.73$   $\mu\text{g/l}$  (range 44–209  $\mu\text{g/l}$ ) and  $0.31 \pm 0.072$   $\mu\text{g/l}$  (range 0.18–0.52  $\mu\text{g/l}$ ), respectively.

No significant differences between the sexes were observed in the mean values of serum selenium and GPx concentrations ( $P = 0.319$  and  $P = 0.194$ , respectively), although serum concentrations of selenium and GPx tended to present higher values among the females ( $117.80 \pm 27.20$  vs  $113.80 \pm 28.30$   $\mu\text{g/l}$  and  $0.32 \pm 0.08$  vs  $0.30 \pm 0.05$   $\mu\text{g/l}$ , respectively) (Table 1).

Table 1  
Characteristics of the study population by gender and smoking status

	Gender		Smoking	
	Female	Male	Female	Male
Total population n(%)	117(59.4%)	80(40.6%)	47(23.9%)	150(76.1%)
Age (years)	$37.63 \pm 42.53$	$18.02 \pm 17.02$	$39.29 \pm 17.75$	$42.63 \pm 17.19^{\text{§}}$
Height (cm)	$161.85 \pm 7.45$	$166.28 \pm 8.61^*$	$163.13 \pm 8.50$	$166.15 \pm 7.77$
Weight (kg)	$66.13 \pm 14.08$	$70.77 \pm 13.76^{\text{§}}$	$67.86 \pm 14.48$	$70.83 \pm 12.38$
BMI (kg/m <sup>2</sup> )	$25.00 \pm 4.91$	$26.08 \pm 4.48$	$25.58 \pm 4.88$	$25.67 \pm 4.24$
Waist (cm)	$90.21 \pm 17.55$	$91.35 \pm 12.81$	$90.49 \pm 16.27$	$93.46 \pm 12.69$
Hip (cm)	$99.90 \pm 9.54$	$99.20 \pm 9.74$	$99.76 \pm 9.98$	$100.14 \pm 8.66$
Waist/hip	$0.89 \pm 0.12$	$0.91 \pm 0.09$	$0.90 \pm 0.11$	$0.92 \pm 0.08$
SBP (mmHg)	$110 \pm 15.44$	$112 \pm 15.40$	$115.23 \pm 15.92$	$113.45 \pm 14.83$
DBP (mmHg)	$70.49 \pm 11.88$	$72 \pm 9.44$	$73.52 \pm 10.92$	$72.35 \pm 8.17$
FBS (mg/dL)	$85.10 \pm 14.22$	$86.62 \pm 21.37$	$86.46 \pm 18.83$	$84.63 \pm 13.17$
LDL (mg/dL)	$110.87 \pm 32.85$	$110.62 \pm 34.03$	$110.99 \pm 33.13$	$111.23 \pm 34.76$
HDL (mg/dL)	$41.58 \pm 7.25$	$39.97 \pm 8.88$	$41.50 \pm 7.64$	$39.22 \pm 8.80$
TG (mg/dL)	$129.53 \pm 98.86$	$128.75 \pm 83.46$	$126.16 \pm 86.34$	$186.91 \pm 52.91$
TC (mg/dL)	$181.73 \pm 48.49$	$178.64 \pm 50.52$	$181.05 \pm 48.79$	$186.91 \pm 52.91$
Selenium level ( $\mu\text{g/L}$ )	$117.80 \pm 27.20$	$113.80 \pm 28.30$	$117.10 \pm 29.90$	$115.9 \pm 27.10$
GPx (U/mL)	$0.32 \pm 0.08$	$0.30 \pm 0.05$	$0.3162 \pm 0.08$	$0.3161 \pm 0.07$

Values are expressed as mean  $\pm$  SD. Between smoking status and gender groups comparisons were assessed by *t*-test. \* $P < 0.001$ . \*\* $P < 0.01$ .  $^{\text{§}}$  $P < 0.05$ . BMI, body mass index; FBS, fasting blood sugar; TC, total cholesterol; TG, triglycerides; HDL, high-density lipoprotein; LDL, low-density lipoprotein; GPx, glutathione peroxidase; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure.

Table 2  
Characteristics of the study population by age status

	Age (years)					
	18–25	26–35	36–45	46–55	56–65	66–80
Total population n(%)	70(35.5%)	15(7.6%)	45(22.8%)	29(14.7)	32(16.2%)	6(3%)
Male/Female	13/17	4/9	24/21	16/15	16/17	1/4
Smoker/ Nonsmoker	8/21	5/8	11/34	7/24	10/23	1/4
Height (cm)	165.17 ± 9.47	161.42 ± 5.81	165.31 ± 8.30	167.08 ± 7.50	167.08 ± 7.50	167.08 ± 7.50
Weight (kg)	61.48 ± 13.27	68.60 ± 10.43	73.90 ± 12.46	74.95 ± 10.36	73.26 ± 11.03	76.20 ± 16.67*
BMI (kg/m <sup>2</sup> )	21.86 ± 3.56	26.23 ± 3.48	27.26 ± 4.78	26.95 ± 3.76	27.61 ± 3.91	28.40 ± 4.19*
Waist (cm)	79.02 ± 10.55	90.65 ± 9.21	95.16 ± 10.06	98.59 ± 9.60	99.93 ± 11.78	116.20 ± 35.00*
Hip (cm)	95.35 ± 7.32	101.46 ± 7.04	103.45 ± 7.10	103.03 ± 8.34	100.81 ± 10.19	104.600 ± 7.43*
Waist/Hip	0.82 ± 0.69	0.89 ± 0.074	0.91 ± 0.05	0.95 ± 0.08	0.99 ± 0.08	1.09 ± 0.25*
SBP (mmHg)	103.85 ± 13.18	108.46 ± 10.68	115.73 ± 11.93	117.35 ± 12.37	125.81 ± 11.71	128.00 ± 11.51*
DBP (mmHg)	65.53 ± 10.02	71.30 ± 8.82	73.37 ± 8.82	74.03 ± 10.83	78.00 ± 9.60	80.00 ± 9.35*
FBS (mg/dL)	76.96 ± 11.29	78.53 ± 8.53	82.66 ± 17.05	92.74 ± 11.99	97.75 ± 25.22	85.50 ± 18.73*
LDL (mg/dL)	91.26 ± 20.50	90.79 ± 24.51	121.33 ± 33.54	133.38 ± 26.17	127.13 ± 29.37	134.33 ± 34.42*
HDL (mg/dL)	37.96 ± 6.13	35.15 ± 8.47	41.40 ± 8.57	44.66 ± 5.47	42.39 ± 8.13	39.66 ± 2.08*
TG (mg/dL)	74.03 ± 35.48	105.69 ± 73.40	136.38 ± 89.04	165.77 ± 96.53	183.18 ± 128.69	159.25 ± 63.05*
TC (mg/dL)	141.03 ± 25.05	147.07 ± 24.99	189.97 ± 36.93	217.92 ± 48.04	214.00 ± 48.76	219.75 ± 72.53*
Selenium level (µg/L)	124.80 ± 18.30	123.4 ± 20.3	112.1 ± 32.4	105.6 ± 34.5	109.5 ± 30.5	115.6 ± 16.7**
GPx (U/mL)		0.33 ± 0.05	0.30 ± 0.06	0.26 ± 0.04	0.27 ± 0.05	0.27 ± 0.02*

Values are expressed as mean ± SD. Comparison between age categories using one-way ANOVA. \* $P < 0.001$ . \*\* $P < 0.01$ . \*\*\* $P < 0.05$ . GPx, glutathione peroxidase; BMI, body mass index; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; FBS, fasting blood sugar; TC, total cholesterol; TG, triglycerides; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

Of the participants, 47(23.9%) were smoker (Table 1). The mean serum selenium and GPx level of smokers ( $117.10 \pm 29.90$  and  $0.30 \pm 0.05 \mu\text{g/l}$ , respectively) was lower than that of non-smokers ( $115.9 \pm 27.10$  and  $0.3161 \pm 0.07 \mu\text{g/l}$ , respectively), although this was not statistically significant ( $P = 0.811$  and  $P = 0.998$ , respectively) (Table 1).

Participants were divided into six subgroups based on their age. The highest concentrations of selenium and GPx occurred at the age group of 18–25 years old ( $124.8 \pm 18.30 \mu\text{g/l}$  and  $0.36 \pm 0.07 \mu\text{g/l}$ , respectively). Serum selenium and GPx concentrations were lowest in 46–55 years age group ( $105.6 \pm 34.5$  and  $0.26 \pm 0.04$ , respectively). The statistically significant difference for selenium and GPx concentrations, among different age groups is found by conducting one-way ANOVA analysis ( $P = 0.01$ ,  $P < 0.0001$ , respectively) (Table 2).

In our study, 31(16.35%) were obese (BMI >30), 68(35.85%) were overweight ( $25 < \text{Bp}; \text{MI} \leq 30$ ), 83(43.7%) were normal ( $18 < \text{BMI} \leq 25$ ) and 8(4.2%) were underweight (BMI ≤ 18). Serum selenium concentrations fell with increasing BMI category up to obese people (BMI >30), it was highest in BMI ≤ 18 and BMI > 30 ( $128.7 \pm 18.5$  and  $123.90 \pm 35.5$ , respectively) compared other BMI categories. The difference was statistically significant ( $P = 0.004$ ). The highest and lowest GPx concentrations were in BMI <18 ( $0.36 \pm 0.08$ ) and  $25 < \text{BMI} \leq 30$  ( $0.29 \pm 0.04$ ), respectively. There were no significant correlations between these BMI categories and GPx level ( $P = 0.064$ ).

### 3.1. Univariate analysis of factors associated with serum selenium concentration

There were weak but negatively significant association between serum selenium concentrations and age ( $r = -0.205$ ,  $P = 0.006$ ), triglycerides ( $r = 0.156$ ,  $P = 0.038$ ) and cholesterol ( $r = -0.229$ ,  $P = 0.003$ ). Serum GPx levels were negatively associated with weight ( $r = -0.281$ ,  $P = 0.01$ ), BMI ( $r = -0.227$ ,  $P = 0.04$ ), SBP ( $r = -0.447$ ,  $P = 0.00$ ), FBS ( $r = -0.229$ ,  $P = 0.00$ ), LDL ( $r = -0.283$ ,  $P = 0.01$ ), and positively associated with cholesterol ( $r = 0.321$ ,  $P = 0.00$ ) (Table 4).

Table 3  
Characteristics of the study population by BMI status

	BMI (kg/m <sup>2</sup> )			
	<18 (underweight)	>18<25(normal)	>25<30(overweight)	30<(obese)
Total population n (%)	8(4.2%)	83(43.7%)	68(35.85%)	31(16.35%)
Age (years)	28.42 ± 26.60	34.25 ± 16.92	47.34 ± 13.21	49.70 ± 14.31
Male/Female	4/3	32/39	35/31	11/20
Smoker/ Nonsmoker	1/6	17/52	23/43	11/20
Height (cm)	156.22 ± 11.72	165.03 ± 7.99	165.49 ± 7.82	160.50 ± 7.83*
Weight (kg)	41.84 ± 7.79	60.64 ± 8.89	73.77 ± 7.79	85.79 ± 10.88*
Waist (cm)	67.82 ± 10.76	82.93 ± 9.72	96.11 ± 8.16	110.00 ± 16.26*
Hip (cm)	79.92 ± 13.28	95.59 ± 5.35	101.42 ± 7.03	111.82 ± 6.58*
Waist/Hip	0.85 ± 0.15	0.86 ± 0.09	0.94 ± 0.08	0.97 ± 0.13*
SBP (mmHg)	92.14 ± 22.30	107.75 ± 14.58	117.77 ± 13.42	123.09 ± 13.27*
DBP (mmHg)	59.28 ± 11.70	67.45 ± 8.71	75.04 ± 10.30	77.25 ± 10.63*
FBS (mg/dL)	73.57 ± 19.24	80.90 ± 12.36	89.81 ± 19.01	90.22 ± 22.22*
LDL (mg/dL)	85.20 ± 26.23	104.76 ± 31.40	115.22 ± 30.73	112.75 ± 33.11*
HDL (mg/dL)	42.83 ± 11.40	40.11 ± 6.89	40.55 ± 8.90	42.67 ± 7.57
TG (mg/dL)	92.33 ± 34.90	99.22 ± 66.92	156.07 ± 113.46	165.16 ± 90.97*
TC (mg/dL)	155.42 ± 33.98	167.19 ± 46.07	192.66 ± 48.50	210.40 ± 49.85*
Selenium level (µg/L)	128.7 ± 18.5	118.3 ± 21.2	106.4 ± 29.2	123.90 ± 35.5**
GPx (U/mL)	0.36 ± 0.08	0.32 ± 0.07	0.29 ± 0.04	0.30 ± 0.08

Values are expressed as mean ± SD. Comparison between BMI categories using one-way ANOVA. \* $P < 0.001$ . \*\* $P < 0.01$ . \*\*\* $P < 0.05$ . GPx, glutathione peroxidase; BMI, body mass index; FBS, fasting blood sugar; TC, total cholesterol; TG, triglycerides; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure.

Table 4  
Correlation ( $r$ ) between indices of serum selenium status and coronary risk factors

	Selenium	GPx
	$r$	$r$
Age	-0.205**	-0.372*
Height	-0.101	-0.169
Weight	-0.122	-0.281**
BMI	-0.088	-0.227***
Waist	0.086	0.237
Hip	0.030	0.039
Waist/Hip	-0.108	0.337*
Systolic BP	0.106	-0.447*
Diastolic BP	-0.108	-0.229
FBS	0.012	-0.229*
TC	-0.229**	0.321*
LDL	-0.075	-0.283**
HDL	0.060	-0.121
TG	-0.156 <sup>‡</sup>	-0.301*

Correlation were assessed using Pearson correlation coefficients; \* $P < 0.001$ . \*\* $P < 0.01$ . \*\*\* $P < 0.05$ . GPx, glutathione peroxidase; BMI, body mass index; BP, blood pressure; FBS, fasting blood sugar; TC, total cholesterol; TG, triglycerides; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

Table 5  
Comparison of the mean serum levels of selenium, among adults from different countries (18, 20)

Country	Overall mean ( $\mu\text{g/l}$ )
Finland (Helsinki)	41.7
New Zealand (Dunedin)	47.2
Brazil (Rio de Janeiro)	73.2
W. Germany (Mainz)	81.1
Sweden (lund)	85.0
Italy (Rome)	89.8
Japan (Hiroshima)	97.6
Saudi Arabia	102.5
US (Mort.Gr.)	110.2
England (Southampton)	115.7
Iran(Mashhad)	116.0
Canada (Toronto)	158.3

1  $\mu\text{g}$  = 0.0127  $\mu\text{mol}$ .

Our findings demonstrate groups at risk of deficiency, and suggest factors that may influence plasma levels of selenium.

#### 4. Discussion

Selenium is involved in many biochemical processes supporting life. The most important of these processes are cellular respiration, DNA and RNA reproduction, maintenance of cell membrane integrity, and sequestration of free radicals. Selenium is involved in destruction of free radicals through cascading enzyme systems. Hydrogen peroxide is then reduced to water by the selenium-glutathione peroxidase couple. Efficient removal of these superoxide free radicals maintains the integrity of membranes, reduces the risk of cancer, and slows the aging process. Trace element-deficient subjects usually present with common symptoms such as malaise, anemia, infection, skin lesions, and low-grade neuropathy [13]. A lot of studies showed relationship between selenium deficiency and disease, and support this concept [14–17]. This is the first study that has identified various factors which may contribute to a selenium status in a nationally representative sample of Iranian women and men.

The mean serum selenium level for adults observed in this survey was  $116 \pm 27.73 \mu\text{g/mL}$  which was similar to the one described in an exploration in the England and US [18]. In the Nutritional Prevention of Cancer (NPC) Trial [19], a serum selenium level of 80 ng/mL is reflected the minimum level of serum selenium essential in the bloodstream for full construction of seleno-proteins. The table reviews the selenium serum levels in the Iranian population in comparison with different national population data.

Previous studies have reported that serum selenium is not significantly related to gender, although others have reported that healthy women have higher serum selenium concentrations than their male counterparts [21–24]. We did not find significant difference in serum selenium concentrations related to gender. Whether there is a gender difference in serum GPx activity remains controversial [25, 26]. Our study had also failed to find any significant association between gender and serum GPx activity.

Some studies have previously reported that within a healthy population serum selenium concentration are reduced in smokers [27]. While other investigators did not show any relationship between serum selenium concentrations and smoking [28]. In our study, we found no significant differences in serum concentrations of selenium or GPx between smoker subjects and non-smokers. This may be dependent on the type and form of tobacco consumption, which is likely to differ between the two populations.

By other authors, significant variation with regard to age has also been reported [29–31]. However, we did find a negative correlation between serum Se concentration and age until 50 years old. The serum selenium content in Iranian would increase with age when they were older than 50. This decline in younger population of Iranian peoples

may be as a result of food habit change in this group of subjects. Adolescent and more elderly population was more likely to maintain the traditional diet, with a significantly higher consumption fruit, vegetables and carbohydrates, and a lower intake of sweets.

Other investigators have reported that serum selenium concentrations are significantly lower in obese subjects [32], while other studies have reported no significant difference in serum Se concentration between obese and non-obese subjects [10]. In our study, serum Se concentration found to be significantly higher in obese Iranian subjects. Like some previous studies, we found lower serum GPx concentrations in obese peoples compared to non-obese subjects [33].

Some previous studies have found no significant association between serum Se and several coronary risk factors [34]. Other investigators reported a positive and significant relationship serum Se and serum cholesterol, and serum GPx and HDL cholesterol concentrations [10]. Our study did show weak association between serum Se concentration and serum cholesterol and triglycerides Level. There was negative association between serum GPx and weight, BMI, SBP, FBS and LDL cholesterol concentrations, and positive association between serum GPx and serum cholesterol level.

## 5. Conclusion

Supplementation among people with low selenium status has been reported to decreased the incidence rate of various type of illness from prostate cancer to viral infection [35]. On the other hand, for individuals living in region with high selenium intake, selenium supplementation could potentially increase risk of hypertention, diabetes, or hypercholesterolemia [7–9]. These findings call for a thorough evaluation of the risks and benefits associated selenium supplementation. The result of our study, could be used to identify people who have risk factor for low selenium status and would benefit from blood test, if their test determines low serum selenium concentration, they should prescribed a daily selenium supplement and recommended to modify their lifestyle. So that the diseases associated with selenium deficiency can be prevented and their incidences can be then reduced. By this approach, we would eliminate the possibility of toxicity and side effects of selenium supplementation.

## Acknowledgments

The MUMS (Mashhad University of Medical Science) has provided the financial supports for this study. We are particularly grateful to the subjects and their family members who volunteered to participate in this study.

## Declaration of interest

The authors have no conflict of interests to declare.

## References

- [1] Jozanov-Stankov O, Demajo M, Djujic I, Mandic M. Selenium intake as a modulator of responsiveness to oxidative stress. *J Environ Pathol Toxicol Oncol.* 1998;17(3–4):251-57.
- [2] Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J. Role of oxygen radicals in DNA damage and cancer incidence. *Mol Cell Biochem.* 2004;266:37-56.
- [3] Chisolm GM, Steinberg D. The oxidative modification hypothesis of atherogenesis: An overview. *Free Radic Biol Med.* 2000;28:1815-26.
- [4] Knekt P, Marniemi J, Teppo L, Heliövaara M, Aromaa A. Is low selenium status a risk factor for lung cancer? *Am J Epidemiol.* 1998;148:875-82.
- [5] Rayman MP. Food-chain selenium and human health: Emphasis on intake. *Br J Nutr.* 2008;100:254-68.
- [6] Bleys J, Navas-Acien A, Stranges S, Menke A, Miller ER III, Guallar E. Serum selenium and serum lipids in US adults. *Am J Clin Nutr.* 2008;88:416-23.

- [7] Laclaustra M, Navas-Acien A, Stranges S, Ordovas JM, Guallar E. Serum Selenium Concentrations and Hypertension in the US Population. *Circ Cardiovasc Qual Outcomes*. 2009;2:369-76.
- [8] Bleyers J, Navas-Acien A, Guallar E. Serum selenium and diabetes in US adults. *Diabetes Care*. 2007;30:829-34.
- [9] Laclaustra M, Navas-Acien A, Stranges S, Ordovas JM, Guallar E. Serum selenium concentrations and diabetes in US adults: National Health and Nutrition Examination Survey (NHANES) 2003–2004. *Environ Health Perspect*. 2009; DOI: 10.1289/ehp.0900704 [epub 2009 May 15].
- [10] Ghayour-Mobarhan M, Taylor A, New SA, Lamb DJ, Ferns GAA. Determinants of serum copper, zinc and selenium in healthy subjects. *Ann Clin Biochem*. 2005;42(Pt 5):364-75.
- [11] Campillo N, Vinas P, Lopez-Garcia I, Hernandez-Cordoba M. Selenium determination in biological fluids using Zeeman background correction electrothermal atomic absorption spectrometry. *Anal Biochem*. 2000;280:195-69.
- [12] Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. *J Lab Clin Med*. 1967;70:158-69.
- [13] Chan S, Gerson B, Subramaniam S. The role of copper, molybdenum, selenium, and zinc in nutrition and health. *Clin Lab Med* 1998;18(4):673-85.
- [14] Di Silvestro RA. Zinc in relation to diabetes and oxidative disease. *J Nutr*. 2000;130(5S):1509S-11S.
- [15] Huang X, Cuajungco MP, Atwood CS, Moir RD, Tanzi RE, Bush AI. Alzheimer's disease, betaamyloid protein and zinc. *J Nutr*. 2000;130(5S):1488S-92S.
- [16] Powell SR. The antioxidant properties of zinc. *J Nutr*. 2000;130(5S):1447S-54S.
- [17] Simonoff M, Sergeant C, Garnier N, Moretto P, Llabador Y, Simonoff G, Corni C. Antioxidant status (selenium, vitamins A and E) and aging. In: Chance B(Ed). *Free Radicals and Aging (368±397)*. Birkhäuser Verlag, Basel, p. Verlag. 1998.
- [18] Lockitch G. Selenium: Clinical significance and analytical concepts. *Crit Rev Clin Lab Sci*. 1989;27:483-41.
- [19] Raines DA, Kinsara AJ, Eid Fawzy M, Vasudevan S, Mohamed GE, Legayada ES, Al-Rawithi S, El-Yazigi A. Plasma and urinary selenium in Saudi Arabian patients with dilated cardiomyopathy. *Biol Trace Elem Res*. 1999;69:59-58.
- [20] Duffield-Lillico AJ, Reid ME, Turnbull BW. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: A summary report of the Nutritional Prevention of Cancer Trial. *Cancer Epidemiol Biomarkers Prev*. 2002;11:630-39.
- [21] Burguera JL, Burguera M, Galignani M, Alarcon OM, Burguera JA. Blood serum selenium in the province of Merida, Venezuela, related to sex, cancer incidence and soil selenium content. *J Trace Elem Electrolytes Health Dis*. 1990;4:73-77.
- [22] Beaglehole R, Jackson R, Watkinson J, Scragg R, Yee RL. Decreased blood selenium and risk of myocardial infarction. *Int J Epidemiol*. 1990;19:918-22.
- [23] Malvy DJ, Arnaud J, Burtschy B, Richard MJ, Favier A, Houot O, Amédée-Manesme O. Reference values for serum zinc and selenium of French healthy children. *Eur J Epidemiol*. 1993;9:155-61
- [24] McMaster D, Bell N, Anderson P, Love AH. Automated measurement of two indicators of human selenium status, and applicability to population studies. *Clin Chem*. 1990;36:211-16
- [25] Guemouri L, Artur Y, Herbeth B, Jeandel C, Cuny G, Siest G. Biological variability of superoxide dismutase, glutathione peroxidase, and catalase in blood. *Clin Chem*. 1991;37:1932-37.
- [26] Rush JW, Sandiford SD. Plasma glutathione peroxidase in healthy young adults: Influence of gender and physical activity. *Clin Biochem*. 2003;36:345-51.
- [27] Grandjean P, Nielsen GD, Jorgensen PJ, Horder M. Reference intervals for trace elements in blood: Significance of risk factors. *Scand J Clin Lab Invest*. 1992;52:321-37.
- [28] Swanson CA, Longnecker MP, Veillon C, Howe M, Levander OA, Taylor PR, McAdam PA, Brown CC, Stampfer MJ, Willett WC. Selenium intake, age, gender, and smoking in relation to indices of selenium status of adults residing in a seleniferous area. *Am J Clin Nutr*. 1990;52:858-62.
- [29] Tietz NW. *Clinical Guide to Laboratory Tests*. 3rd edn. Philadelphia: WB Saunders Company. 1999.
- [30] Johnson PE, Milne DB, Lykken GI. Effects of age and sex on copper absorption, biological half-life, and status in humans. *Am J Clin Nutr*. 1992;56:917-25.
- [31] Kafai MR, Ganji V. Sex, age, geographical location, smoking, and alcohol consumption influence serum selenium concentrations in the USA: Third National Health and Nutrition Examination Survey, 1988–1994. *J Trace Elem Med Biol*. 2003;17:13-18.
- [32] Gjorup I, Gjorup T, Andersen B. Serum selenium and zinc concentrations in morbid obesity. Comparison of controls and patients with jejunoileal bypass. *Scand J Gastroenterol*. 1988;23:1250-52.
- [33] Ozata M, Mergen M, Oktenli C, Aydin A, Sanisoglu SY, Bolu E, Yilmaz MI, Sayal A, Isimer A, Ozdemir IC. Increased oxidative stress and hypozincemia in male obesity. *Clin Biochem*. 2002;35:627-3.
- [34] Jossa F, Trevisan M, Krogh V, Farinaro E, Giumetti D, Fusco G, Galasso R, Panico S, Frascatore S, Mellone C. Serum selenium and coronary heart disease risk factors in southern Italian men. *Atherosclerosis*. 1991;87:129-34.
- [35] Duffield-Lillico AJ, BL Dalkin, ME Reid. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: An analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. *BJU International*. 2003;91(7):608-12.